Intranasal esketamine represents a new opportunity for the mental health community to provide relief for patients who are suffering from depression with a different approach. As a rapidly acting agent, the drug commonly known by it’s brand name Spravato can provide alleviation to depression symptoms in a matter of days as opposed to the traditional weeks of wait time.

Despite the promising attributes of this new treatment option, cumulative data that calls for more restraints¬†and cautions regarding it’s use should be heeded. Ketamine is a drug that poses many concerns including abuse, rapid relapse, and the risk of potential suicide associated with treatment discontinuation.

Read More